Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2015 (2015), Article ID 137136, 8 pages
Research Article

Inhibition of Corneal Neovascularization by Subconjunctival Injection of Fc-Endostatin, a Novel Inhibitor of Angiogenesis

1Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
2Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
3Center of Cancer Systems Biology, St. Elizabeth’s Medical Center, Tufts University School of Medicine, Boston, MA 02111, USA
4Departments of Oncology and Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA

Received 19 August 2014; Revised 16 December 2014; Accepted 12 January 2015

Academic Editor: Juliana L. Dreyfuss

Copyright © 2015 Junko Yoshida et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


We assessed the antiangiogenic effects of subconjunctival injection of Fc-endostatin (FcE) using a human vascular endothelial growth factor-induced rabbit corneal neovascularization model. Angiogenesis was induced in rabbit corneas through intrastromal implantations of VEGF polymer implanted 2 mm from the limbus. NZW rabbits were separated into groups receiving twice weekly subconjunctival injections of either saline; 25 mg/mL bevacizumab; 2 mg/mL FcE; or 20 mg/mL FcE. Corneas were digitally imaged at 5 time points. An angiogenesis index (AI) was calculated (vessel length (mm) × vessel number score) for each observation. All treatment groups showed a significant decrease in the vessel length and AI compared to saline on all observation days (). By day 15, FcE 2 inhibited angiogenesis significantly better than FcE 20 (). There was no significant difference between FcE 2 and BV, although the values trended towards significantly increased inhibition by BV. BV was a significantly better inhibitor than FcE 20 by day 8 (). FcE was safe and significantly inhibited new vessel growth in a rabbit corneal neovascularization model. Lower concentration FcE 2 exhibited better inhibition than FcE 20, consistent with previous FcE studies referencing a biphasic dose-response curve. Additional studies are necessary to further elucidate the efficacy and clinical potential of this novel angiogenesis inhibitor.